BMRN Q2 2018 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$373M+17.5% YoY

Gross Profit

$294M78.8% margin

Operating Income

-$25M-6.8% margin

Net Income

-$17M-4.5% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

-0.2%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$56M

Stock-Based Comp.

$39M

Balance Sheet

Total Assets

$4.6B

Total Liabilities

$1.7B

Stockholders' Equity

$2.9B

Cash & Equivalents

$427M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$373M	$317M	+17.5%
Gross Profit	$294M	$261M	+12.5%
Operating Income	-$25M	-$39M	+34.9%
Net Income	-$17M	-$37M	+54.4%

Revenue Segments

Product

$368M50%

Product Four

$128M17%

Product Three

$109M15%

Product Two

$91M12%

Product One

$24M3%

Product Six

$11M1%

Product Five

$5M1%

Geographic Segments

UNITED STATES

$163M44%

Europe

$107M29%

Latin America

$58M16%

Rest Of World

$45M12%